Patient Square Capital’s BioNTech BNTX Stock Holding History

Patient Square Capital’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.5M	Buy	+134,429	New	+$12.7M	1.94%	13

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

Patient Square Capital's BNTX Position: Q2 2026 in Review

Patient Square Capital opened a new position in BioNTech (BNTX) in Q2 2026: 134,429 shares worth $12.5M. The stake represents 1.94% of the portfolio and ranks #13 among its holdings.

281 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

Patient Square Capital held 134,429 shares of BioNTech worth $12.5M as of Q2 2026.
BioNTech was a new Patient Square Capital position in Q2 2026.
BioNTech made up 1.94% of Patient Square Capital's portfolio in Q2 2026, its #13 holding.
281 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Patient Square Capital's 13F filing for Q2 2026, filed 12 Aug 2026.